NOX 0.00% 6.6¢ noxopharm limited

Thanks, though Graham seems to agree with my proposition:"The...

  1. 1,610 Posts.
    lightbulb Created with Sketch. 409
    Thanks, though Graham seems to agree with my proposition:

    "The VISION study compared Lu-PSMA-617 with standard of care in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received at least two previous lines of therapy ...This compares with the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda in men with end-stage mCRPC who had progressed on at least three previous lines of therapy."

    (from today's announcement; my emphasis)
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
6.6¢
Change
0.000(0.00%)
Mkt cap ! $19.28M
Open High Low Value Volume
6.6¢ 6.6¢ 6.6¢ $336 5.089K

Buyers (Bids)

No. Vol. Price($)
1 14893 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 12000 1
View Market Depth
Last trade - 11.03am 01/07/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.